Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy

Do electronic patient-reported outcomes with vital sign monitoring improve quality of life (QOL) for patients with ERBB2 (formerly HER2 or HER2/neu)-positive metastatic breast cancer undergoing trastuzumab deruxtecan (T-DXd) treatment?In this randomized clinical trial of 111 patients with ERBB2-positive metastatic breast cancer undergoing T-DXd treatment, symptom tracking and vital sign monitoring were associated with higher QOL scores at week 24 compared with usual care, with significant improvements in global health status and functional domains.These findings suggest that incorporating a comprehensive monitoring strategy into clinical practice may help maintain or prevent QOL deterioration among patients receiving T-DXd treatment.

Corresponding Author: Takafumi Sangai, MD, PhD, Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, 1-15-1 Kitazato, Minami-ku, Sagamihara-shi, Kanagawa 252-0374, Japan (sangai@med.kitasato-u.ac.jp).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.